Close Menu

NEW YORK – OraSure Technologies reported after the close of the market on Monday that its fourth quarter revenues rose 27 percent year over year due to strong sales of molecular sample collection devices.

For the three months ended Dec. 31, 2020, the point-of-care diagnostic testing and specimen collection device manufacturer reported revenues of $62.9 million, up from $49.7 million a year ago and above the analysts' average estimate of $57.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.